Unum Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Unum
Therapeutics, a clinical stage biopharmaceutical company developing
a universal cellular immunotherapy to treat multiple cancers, today
announced that President and Chief Executive Officer Chuck
Wilson will present at the Leerink Partners Roundtable Series: Rare
Disease & Immuno-Oncology on September 29, 2016 at 12:30 pm ET. The
conference is being held September 28-29, 2016 at the Lotte New York
Palace in New York.

Unum Therapeutics

Unum uses proprietary T-cell engineering technology in combination with
tumor-targeting antibodies to activate the body’s own immune system to
fight cancer. The Company’s lead program, which combines Unum’s
proprietary Antibody-Coupled T-cell Receptor (ACTR) technology with
rituximab, is in Phase 1 clinical testing to assess its safety and
efficacy. The company is headquartered in Cambridge, MA. For more
information, visit www.unumrx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160921005322/en/